Electroporation System for Treatment of Hepatic Tumors

Information

  • Research Project
  • 6735852
  • ApplicationId
    6735852
  • Core Project Number
    R43CA107462
  • Full Project Number
    1R43CA107462-01
  • Serial Number
    107462
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/2004 - 20 years ago
  • Project End Date
    12/31/2006 - 18 years ago
  • Program Officer Name
    WOLPERT, MARY K
  • Budget Start Date
    4/1/2004 - 20 years ago
  • Budget End Date
    12/31/2006 - 18 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/30/2004 - 20 years ago

Electroporation System for Treatment of Hepatic Tumors

[unreadable] DESCRIPTION (provided by applicant): Current treatment methods for unresectable primary liver tumors and liver metastasis from distant sites are inadequate. Investigation of novel treatment strategies is warranted due to the lack of effective therapy. [unreadable] [unreadable] In vivo electroporation has been shown to dramatically improve the uptake of therapeutic agents in targeted regions of tissue. During previous studies, Ichor investigated the anti-tumor and toxicological effects associated with electroporation mediated delivery of a chemotherapeutic agent. These studies, as well as subsequent experiments potentiating the intratumoral delivery of nucleic acids, demonstrate the basic merit of the approach. However, current methods and devices require an open surgical procedure for electroporation application. This is a critical limitation that could preclude widespread implementation of the approach. [unreadable] [unreadable] In light this limitation, Ichor proposes a Phase I study to develop an application system that can be applied in a minimally invasive fashion for the intratumoral delivery of therapeutic agents to hepatic tumors. The proposed scope of work includes research and development of functional prototypes including a pilot evaluation study in large animals. Successful completion of the proposed SBIR Phase I will result in a device suitable for use in a Phase II clinical study as well as out-licensing for use by strategic partners. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    276822
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:276822\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ICHOR MEDICAL SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92121
  • Organization District
    UNITED STATES